ProfileJobs

Sucampo Pharmaceuticals

Suggest Edit
    • Healthcareclinicspharma

    Sucampo Pharmaceuticals is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

    Revenue(FY, 2016)
    $230.1 M

    Employee Rating

    3.2More
    StateClosed
    TypeSubsidiary
    Parent CompanyMallinckrodt Pharmaceuticals
    HQRockville, US
    Founded1996
    Websitesucampo.com
    Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Sucampo Pharmaceuticals Office Locations

    Sucampo Pharmaceuticals has offices in Rockville, Chiyoda, Chuo Ward, Kita Ward and in 3 other locations
    Rockville, US (HQ)
    805 King Farm Blvd #550
    Chiyoda, JP
    NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
    Chuo Ward, JP
    Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
    Kita Ward, JP
    Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
    Sanda-shi, JP
    4-1 Techno-Park
    Zug, CH
    22 Baarerstrasse
    Show all (7)
    Report incorrect company information

    Sucampo Pharmaceuticals Financials and Metrics

    Summary Metrics

    Founding Date

    		1996
    Sucampo Pharmaceuticals is a subsidiary of Mallinckrodt Pharmaceuticals

    Sucampo Pharmaceuticals Revenue

    Embed Graph
    View revenue for all periods
    Sucampo Pharmaceuticals's revenue was reported to be $230.06 m in FY, 2016 which is a 50.2% increase from the previous period.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Revenue

    		89.6m115.5m153.2m230.1m

    Revenue growth, %

    		29%33%50%

    Cost of goods sold

    		12.4m16.3m36.7m76.0m

    Gross profit

    		77.2m99.2m116.4m154.1m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Revenue

    		21.2m22.2m24.1m31.5m29.5m34.9m33.4m47.2m52.0m57.9m56.3m59.9m61.3m

    Cost of goods sold

    		6.3m3.5m3.8m5.0m6.1m7.3m5.3m23.3m20.4m15.6m16.9m17.0m17.4m

    Gross profit

    		14.9m18.6m20.3m26.5m23.4m27.6m28.2m23.9m31.6m42.3m39.4m42.9m43.8m

    Gross profit Margin, %

    		70%84%84%84%79%79%84%51%61%73%70%72%72%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		44.1m71.6m108.3m198.3m

    Accounts Receivable

    		5.4m5.3m22.8m43.0m

    Inventories

    		209.0k3.4m33.1m23.5m

    Current Assets

    		113.4m122.3m251.4m307.2m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Cash

    		39.9m56.1m53.5m56.1m59.6m71.3m91.5m130.1m128.0m128.5m243.5m84.7m75.0m

    Accounts Receivable

    		2.7m4.4m4.8m8.5m8.2m8.2m6.7m16.1m18.2m20.7m20.5m19.8m33.1m

    Inventories

    		261.0k455.0k423.0k133.0k328.0k308.0k296.0k24.4m21.6m24.2m23.0m23.1m24.2m

    Current Assets

    		105.7m122.6m119.3m124.1m120.9m136.7m161.4m228.1m237.7m237.5m322.4m165.1m190.1m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		6.4m13.1m33.4m18.5m

    Depreciation and Amortization

    		1.5m10.6m45.7m

    Inventories

    		(163.0k)(1.4m)(1.2m)

    Accounts Payable

    		2.2m(1.7m)(2.8m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    		4.3m675.0k2.4m3.8m6.4m16.0m23.2m(4.1m)(4.9m)3.2m4.6m(176.5m)(166.2m)

    Depreciation and Amortization

    		1.1m361.0k721.0k984.0k215.0k433.0k15.6m30.1m37.9m7.4m14.9m22.4m

    Inventories

    		(218.0k)(245.0k)(211.0k)74.0k328.0k(308.0k)(296.0k)1.8m309.0k(2.0m)490.0k370.0k(708.0k)

    Accounts Payable

    		(2.4m)(1.6m)(2.0m)(1.7m)1.4m(221.0k)785.0k(6.3m)(5.8m)(4.1m)(1.2m)458.0k(4.5m)
    show all
    Show all financial metrics
    Report incorrect company information

    Competitors

    Durect
    Healthcare - Public
    Zogenix
    Healthcare - Public
    Clinigen Group
    Healthcare - Public
    BTG
    Healthcare - Subsidiary
    Compare competitors

    Sucampo Pharmaceuticals Online and Social Media Presence

    Embed Graph
    Report incorrect company information

     Sucampo Pharmaceuticals Frequently Asked Questions

    • When was Sucampo Pharmaceuticals founded?

      Sucampo Pharmaceuticals was founded in 1996.

    • What is Sucampo Pharmaceuticals revenue?

      Latest Sucampo Pharmaceuticals annual revenue is $230.1 m.

    • Who are Sucampo Pharmaceuticals competitors?

      Competitors of Sucampo Pharmaceuticals include Durect, Zogenix and Clinigen Group.

    • Where is Sucampo Pharmaceuticals headquarters?

      Sucampo Pharmaceuticals headquarters is located at 805 King Farm Blvd #550, Rockville.

    • Where are Sucampo Pharmaceuticals offices?

      Sucampo Pharmaceuticals has offices in Rockville, Chiyoda, Chuo Ward, Kita Ward and in 3 other locations.

    • How many offices does Sucampo Pharmaceuticals have?

      Sucampo Pharmaceuticals has 7 offices.

    Need Data?

    Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

    Learn more